**Prostate-specific antigen (PSA) response in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC) treated with enzalutamide (ENZA): Results from PROSPER**

By: Sternberg C.N.¹, Fizazi K.², Saad F.³, Ratheborg P.⁴, Shore N.⁵, Demirhan E.⁶, Modelska K.⁷, Phung D.⁸, Krivoshik A.⁹, Hussain M.¹⁰

¹San Camillo and Forlanini Hospitals, Dept. of Medical Oncology, Rome, Italy, ²Institut Gustave Roussy, University of Paris Sud, Dept. of Medical Oncology, Villejuif, France, ³Centre hospitalier de l’Université de Montréal, University of Montreal, Dept. of Surgery, Montreal, Canada, ⁴Herlev Hospital, Dept. of Urology, Herlev, Denmark, ⁵Carolina Urologic Research Center, Dept. of Urology, Myrtle Beach, United States of America, ⁶Pfizer, Inc., Dept. of Biostatistics, San Francisco, United States of America, ⁷Pfizer, Inc., Dept. of Clinical Development, San Francisco, United States of America, ⁸Astellas Pharma, Inc., Dept. of Biostatistics, Northbrook, United States of America, ⁹Astellas Pharma, Inc., Dept. of Medical Science and Dept. of Oncology, Chertsey, United Kingdom, ¹⁰Northwestern University, Dept. of Hematology Oncology, Chicago, United States of America

**Patient-reported outcome measures in men with non-metastatic castration-resistant prostate cancer: Baseline data from the PROSPER trial**

By: Tombal B.¹, Hussain M.², Penson D.³, Attard G.⁴, Sternberg C.N.⁵, Phung D.⁶, Naidoo S.⁷, Modelska K.⁸, Demirhan E.⁹, Ramaswamy K.¹⁰, Ivanescu C.¹¹, Saad F.¹²

¹Cliniques Universitaires Saint-Luc, Division of Urology, Brussels, Belgium, ²Northwestern University Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Chicago, United States of America, ³Vanderbilt University Medical Center, Dept. of Urologic Surgery, Nashville, United States of America, ⁴The Institute of Cancer Research and the Royal Marsden, Treatment Resistance, Surrey, United Kingdom, ⁵San Camillo-Forlanini Hospital, Medical Oncology, Rome, Italy, ⁶Astellas Pharma Inc, Biostatistics, Leiden, Netherlands, The, ⁷Astellas Pharma Inc, Dept. of Oncology, Chertsey, United Kingdom, ⁸Pfizer Inc, Dept. of Oncology, San Francisco, United States
606 Radium-223 re-treatment in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up from an international, open-label, phase 1/2 study


1 Akershus University Hospital, Dept. of Oncology, Lørenskog, Norway, 2 GU Research Network, LLC, Dept. of Medical Oncology, Omaha, NE, United States of America, 3 Associated Medical Professionals of New York, PLLC, Dept. of Radiation Oncology, Syracuse, NY, United States of America, 4 Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, University of Cordoba, Dept. of Oncology, Cordoba, Spain, 5 Meir Medical Center, Genitourinary Oncology Service, Kfar Saba, Israel, 6 Cancer Center Nordlands University, Dept. of Radiation Sciences, Umeå, Sweden, 7 Rambam Health Care Campus, Dept. of Oncology, Haifa, Israel, 8 Fondazione Istituto Nazionale Tumori Oncologia Medica Genitourinaria, Dept. of Medical Oncology, Milan, Italy, 9 Hadassah Hebrew University Medical Center, Dept. of Oncology, Jerusalem, Israel, 10 Kuopio University Hospital, Dept. of Oncology, Kuopio, Finland, 11 Rabin Medical Center—Davidoff Center, Dept. of Urology and Oncology, Petah Tikva, Israel, 12 Romagnolo Scientific Institute for the Study and Care of Cancer—IRST IRCCS, Nuclear Medicine Therapeutic Unit, Meldola, Italy, 13 Hospital Universitario Virgen de la Victoria, Dept. of Medical Oncology, Málaga, Spain, 14 Bayer Pharma AG, Pharmaceuticals, Dept. of Oncology Radium & OncoMed, Basel, Switzerland, 15 Bayer Pharma AG, Dept. of Global Clinical Development, Basel, Switzerland, 16 Bayer HealthCare Pharmaceuticals, Dept. of Global Research & Development Statistics, Whippany, NJ, United States of America, 17 Tulane Cancer Center, Dept. of Medicine and Urology, New Orleans, LA, United States of America

607 Radioligand therapy with Lutetium 177-labeled PSMA-I&T for metastatic castration-resistant prostate cancer: Clinical experience with 100 consecutive patients

By: Heck M., Schwaiger S., Knorr K., Retz M., Maurer T., Janssen F., D’Alessandria C., Wester H-J., Gschwend J., Schwaiger M., Tauber R., Eiber M.

1 Rechts der Isar University Hospital, Technical University of Munich, Dept. of Urology, Munich, Germany, 2 Rechts der Isar University Hospital, Technical University of Munich, Dept. of Nuclear Medicine, Munich, Germany, 3 Technical University of Munich, Dept. of Pharmaceutical Radiochemistry, Gauting, Germany

608 Clinical experience with PSMA-Actinium-225 radioligand therapy in end-stage metastatic castration-resistant prostate cancer patients

By: Van Der Doelen M., Mehra N., Van Oort I., Janssen M., Haberkorn U.
**AR-V7 in peripheral whole blood of castration-resistant prostate cancer patients: Association with treatment-specific outcome under abiraterone and enzalutamide**

By: Seitz A-K. 1, Thoene S. 2, Bietenbeck A. 2, Nawroth R. 1, Tauber R. 1, Thalgott M. 1, Schmid S. 1, Secci R. 2, Retz M. 1, Gschwend J. 1, Ruland J. 2, Winter C. 2, Heck M. 1

1Rechts der Isar University Hospital, Technical University of Munich, Dept. of Urology, Munich, Germany, 2Rechts der Isar University Hospital, Technical University of Munich, Institute of Clinical Chemistry and Pathobiochemistry, Munich, Germany

**Outcomes of crossover between androgen receptor targeting drugs in the castration resistant prostate cancer registry (CAPRI)**

By: Kuppen M. 1, Westgeest H. 2, Van Den Eertwegh F. 3, Van Mooreselaar J. 4, De Wit R. 5, Van Oort I. 6, Aben K. 7, Verhoeven R. 7, Van Den Bergh F. 8, Coenen J. 9, Uyl-De Groot C. 1, Gerritsen W. 10

1Erasmus University, Institute for Medical Technology Assessment, Rotterdam, Netherlands, The, 2Amphia Hospital, Dept. of Internal Medicine, Breda, Netherlands, The, 3VU University Medical Center, Dept. of Medical Oncology, Amsterdam, Netherlands, The, 4VU University Medical Center, Dept. of Urology, Amsterdam, Netherlands, The, 5Eramus MC Cancer Institute, Dept. of Medical Oncology, Rotterdam, Netherlands, The, 6Radboud University Medical Center, Dept. of Urology, Nijmegen, Netherlands, The, 7Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands, The, 8University Medical Center Groningen, Dept. of Radiation Oncology, Groningen, Netherlands, The, 9Isala Klinieken, Dept. of Medical Oncology, Zwolle, Netherlands, The, 10Radboud University Medical Center, Dept. of Medical Oncology, Nijmegen, Netherlands, The

**Sipuleucel-T immunotherapy for castrate-resistant prostate cancer modulates soluble B7-H3: A novel mechanism of action**

By: Chang A. 1, Nair S. 2, George D. 3, Inman B. 1

1Duke University, Dept. of Urology, Durham, United States of America, 2Duke University, Dept. of Surgery, Durham, United States of America, 3Duke University, Dept. of Medical Oncology, Durham, United States of America

**Definitive therapy for men with newly-diagnosed oligometastatic prostate cancer: Initial surgical outcomes from a phase II study**

By: Gupta M. 1, Srivastava A. 1, Reyes D. 1, Trock B. 1, Tran P. 2, Allaf M. 1, Bivalacqua T. 1, Carter H. 1, Ross A. 1, Partin A. 1, Pienta K. 1, Pavlovich C. 1
613 Influence of high and low disease volume on docetaxel response in M1 Ca prostate in the STAMPEDE trial

By: Hoyle A.P. ¹, Ali A. ², Douis M. ³, Sydes M. ⁴, James N. ⁵, Clarke N. ⁶
¹Christie NHS Foundation trust, Dept. of Uro-Oncology, Manchester, United Kingdom, ²Cancer research Manchester institute, Belfast- Movember Centre of Excellence, Manchester, United Kingdom, ³University Hospital Birmingham, Dept. of Uro-Radiology, Birmingham, United Kingdom, ⁴University College London, Medical Research Unit, Clinical Trial team, London, United Kingdom, ⁵University Hospital Birmingham, Dept. of Oncology, Birmingham, United Kingdom, ⁶Christie NHS Foundation trust, Dept. of Uro- oncology, Manchester, United Kingdom

614 Systemic Immune-Inflammation Index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients

By: Fan L. ¹, Dong B. ¹, Wang R. ², Chi C. ¹, Pan J. ¹, Zhu Y. ¹, Zhou L. ¹, Xue W. ¹
¹Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Dept. of Urology, Shanghai, China, ²Shanghai Jiaotong University Affiliated No. 6 Hospital, Shanghai Institute of Ultrasound in Medicine, Dept. of Ultrasonography, Shanghai, China

615 Prognostic factors for oncologic outcomes in metastatic chemotherapy-naïve castration-resistant prostate cancer with enzalutamide

By: Choi S.Y. ¹, Ryu J. ¹, Lee J. ¹, Lee W. ¹, Chae H.K. ¹, Choi W. ¹, Kyung Y.S. ¹, Park S. ², Moon K.H. ², You D. ¹, Jeong I.G. ¹, Hong J.H. ¹, Ahn H. ¹, Kim C-S. ¹
¹Asan Medical Center, Dept. of Urology, Seoul, Korea, South, ²Ulsan University Hospital, Dept. of Urology, Ulsan, Korea, South

616 Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: Utilization of neutrophil-to-lymphocyte ratio

By: Koo K.C. ¹, Lee J.S. ², Kang S.K. ¹, Kim J.W. ¹, Lee K.S. ¹, Kim D.K. ¹, Ha Y.S. ¹, Cho K.S. ¹, Rha K.H. ², Hong S.J. ², Chung B.H. ¹
¹Gangnam Severance Hospital, Dept. of Urology, Seoul, Korea, South, ²Shinchon Severance Hospital, Dept. of Urology, Seoul, Korea, South

Summary
A. Omlin, St. Gallen (CH)